08/09/2017 Guerbet Statement Following Medical Imaging Drugs Advisory Committee September 8, 2017

Princeton (NJ, USA) Magnetic resonance imaging (MRI) is a widely used diagnostic procedure which is critical to patient health. And vital to MRI are the contrast agents that give physicians a sharper, more accurate picture of tissue than they would otherwise be able to have.  There are two...


31/03/2017 Guerbet concurs with the PRAC Recommendations on Gadolinium-based Contrast Agents

Princeton, NJ, 31 March 2017 – Guerbet LLC. takes note of the recent recommendations issued March 10, 2017 by the European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC), on Gadolinium-based Contrast Agents - procedure under Article 31 of Directive 2001/83/EC.


24/06/2016 Guerbet Honored With Supplier Horizon Award from Premier Inc.

Princeton, NJ, 23 June 2016 – Guerbet announced that it has been named a winner of Premier Inc.’s Supplier Horizon Award


29/09/2014 Guerbet Receives FDA’s Drug Shortage Assistance Award

Guerbet LLC, USA (September 29, 2014)


Displaying results ###SPAN_BEGIN###%s to %s out of ###SPAN_BEGIN###%s
<< First < Previous 1-7 8-14 15-21 22-26 Next > Last >>